恩帕吉菲
医学
心肌梗塞
心力衰竭
内科学
心脏病学
疾病
肾脏疾病
重症监护医学
2型糖尿病
糖尿病
内分泌学
作者
Javed Butler,W. Schuyler Jones,Jacob A. Udell,Stefan D. Anker,Mark C. Petrie,Josephine Harrington,Michaela Mattheus,Isabella Zwiener,Offer Amir,M. Cecilia Bahit,Johann Bauersachs,Antoni Bayés‐Genís,Yundai Chen,Vijay Chopra,Gemma A. Figtree,Junbo Ge,Shaun G. Goodman,Nina Gotcheva,Shinya Goto,Tomasz Gąsior
标识
DOI：10.1056/nejmoa2314051
摘要
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
pluto
忐忑的黑猫
jenningseastera
科研小民工
bc
森鹿
余味
午见千山
Cherish
827584450
cdercder
归尘
平常的毛豆
Luka
善良的剑通
iNk
HEAUBOOK
Xiaoxiao
斯寜
蒋时晏
皖公网安备34019202002308
